Stockscreener 앱 받기
21.90
4.63%
0.97
시간 외 거래:
21.90
전일 마감가:
$20.93
열려 있는:
$21.2
하루 거래량:
780.09K
Relative Volume:
2.04
시가총액:
$812.40M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+8.31%
1개월 성능:
+69.77%
6개월 성능:
+26.81%
1년 성능:
-25.05%
1일 변동 폭
$20.95
$21.95
1주일 범위
$19.87
$24.25
52주 변동 폭
$10.01
$29.70
Ceribell Inc Stock (CBLL) Company Profile
명칭
Ceribell Inc
전화
(800) 436-0826
주소
360 N. PASTORIA AVENUE, SUNNYVALE
CBLL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
21.90 | 776.41M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
128.47 | 218.16B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.19 | 137.24B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.31 | 135.41B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.57 | 128.03B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.38 | 48.21B | 5.88B | 1.34B | 799.60M | 2.3489 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Raymond James | Strong Buy |
| 2025-06-24 | 개시 | BTIG Research | Buy |
| 2025-04-04 | 개시 | Ladenburg Thalmann | Buy |
| 2024-11-05 | 개시 | BofA Securities | Buy |
| 2024-11-05 | 개시 | Canaccord Genuity | Buy |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 개시 | William Blair | Outperform |
모두보기
Ceribell Inc 주식(CBLL)의 최신 뉴스
Ceribell stock price target reiterated at $30 by BTIG, citing growth - Investing.com Canada
BTIG Reiterates Buy Rating for CeriBell (CBLL) With Target Price of $30 | CBLL Stock News - GuruFocus
Ceribell extends leases for Sunnyvale offices through January 2028 By Investing.com - Investing.com Nigeria
Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells 32,728 Shares of Stock - MarketBeat
FDA Clears Ceribell’s AI-Powered EEG as First Device for Continuous Delirium Monitoring - HIT Consultant
Ceribell, Inc. Extends Sunnyvale Office Leases - TipRanks
Ceribell extends leases for Sunnyvale offices through January 2028 - Investing.com
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution - Yahoo Finance
Josef Parvizi Sells 25,000 Shares of CeriBell (NASDAQ:CBLL) Stock - MarketBeat
Ceribell receives FDA 510K clearance for delirium screening, monitoring device - MSN
CeriBell (NASDAQ:CBLL) Shares Down 5.4% on Insider Selling - MarketBeat
Risk Analysis: Will CeriBell Inc stock split attract more investorsEarnings Miss & Verified Short-Term Trading Plans - moha.gov.vn
Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells 5,000 Shares of Stock - MarketBeat
Ceribell director Robertson sells $100k in CBLL stock By Investing.com - Investing.com South Africa
Ceribell director Robertson sells $100k in CBLL stock - Investing.com
FDA OKs Ceribell’s Delirium Monitoring Solution - Medical Product Outsourcing
Buy Rating Affirmed for Ceribell, Inc. Due to Innovative Neonate Technology and FDA Clearance - TipRanks
Ceribell, Inc.’s Delirium Solution Gains Early FDA Clearance, Boosting Market Potential and Supporting Buy Rating - TipRanks
Ceribell, Inc. (CBLL) Gets a Buy from TD Cowen - The Globe and Mail
CeriBell Shares Rise 5.4% After FDA Clears First-of-Its-Kind Delirium EEG Tool - Nasdaq
There's Reason For Concern Over CeriBell, Inc.'s (NASDAQ:CBLL) Massive 69% Price Jump - 富途牛牛
CeriBell (NASDAQ:CBLL) Shares Gap UpTime to Buy? - MarketBeat
Ceribell stock price target raised to $29 from $20 at TD Cowen on FDA clearance - Investing.com
CeriBell Says FDA Clears Delirium Monitoring Solution; Shares Rise - marketscreener.com
Ceribell, Inc. Gains FDA Clearance for Delirium Device - TipRanks
Ceribell jumps on FDA clearance of brain monitoring device - TradingView — Track All Markets
Ceribell, Inc. Receives FDA Clearance for Delirium Monitoring Solution - TradingView — Track All Markets
Ceribell receives FDA 510k clearance for delirium screening, monitoring device - TipRanks
FDA clears Ceribell’s delirium monitoring system for ICU patients - Investing.com
FDA clears Ceribell’s delirium monitoring system for ICU patients By Investing.com - Investing.com Nigeria
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution - The Manila Times
Ceribell (Nasdaq: CBLL) gets FDA 510(k) clearance for first delirium monitoring device - Stock Titan
Ceribell CEO Chao Xingjuan sells $470k in CBLL stock By Investing.com - Investing.com Australia
CeriBell (NASDAQ:CBLL) CEO Sells $470,500.00 in Stock - MarketBeat
Ceribell CEO Chao Xingjuan sells $470k in CBLL stock - Investing.com
Ceribell Insider Sold Shares Worth $470,500, According to a Recent SEC Filing - marketscreener.com
David Foehr Sells 5,265 Shares of CeriBell (NASDAQ:CBLL) Stock - MarketBeat
Ceribell’s Foehr David sells $88k in Ceribell stock By Investing.com - Investing.com Australia
Ceribell’s Foehr David sells $88k in Ceribell stock - Investing.com India
Ceribell Senior VP David Foehr Sells 5,265 Shares - TradingView
VP Foehr Sells 5,265 ($88.6K) Of CeriBell Inc [CBLL] - TradingView
Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells 827 Shares of Stock - MarketBeat
Geode Capital Management LLC Has $8.39 Million Stock Position in CeriBell, Inc. $CBLL - MarketBeat
CEO Chao Files To Sell 25,000 Of CeriBell Inc [CBLL] - TradingView
Robertson of Ceribell sells $13k in shares By Investing.com - Investing.com Nigeria
Insider Selling: CeriBell (NASDAQ:CBLL) CEO Sells 25,000 Shares of Stock - MarketBeat
CeriBell (NASDAQ:CBLL) CTO Sells $136,455.36 in Stock - MarketBeat
Robertson of Ceribell sells $13k in shares - Investing.com
Ceribell Director Rebecca B. Robertson Sells 827 Shares - TradingView
Chmn Robertson Sells 827 ($13.8K) Of CeriBell Inc [CBLL] - TradingView
Ceribell Inc (CBLL) 재무 분석
Ceribell Inc (CBLL)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.42%
0.91%
자본화:
|
볼륨(24시간):